已收盘 10-04 16:00:00 美东时间
-0.450
-4.94%
RBC Capital analyst Luca Issi reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform and maintains $24 price target.
08-14 00:44
Lexeo Therapeutics press release (NASDAQ:LXEO): Q2 GAAP EPS of -$0.64. As of June 30, 2024, cash and cash equivalents were $175.0 million, More on Lexeo Therapeutics Lexeo: Higher Dosing LX2006 Could ...
08-12 21:10
Lexeo Therapeutics Inc Says Cash and Cash Equivalents of $175.0 Mln Expected to...
08-12 19:06
Lexeo Therapeutics Inc - Qtrly Shr Loss $0.64
08-12 19:05
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operationa...
08-12 19:00
Lexeo Therapeutics Inc : Leerink Partners Raises Target Price to $22 From $19
07-16 11:50
7月16日,Lexeo Therapeutics(LXEO.US)宣布了用于治疗弗里德赖希共济失调(FA)心肌病在研基因疗法LX2006的积极中期数据。
07-16 10:55
Shares of Lexeo Therapeutics (NASDAQ:LXEO) tumbled 24% after the company reported interim Phase 1/2 clinical data for its drug LX2006 for the treatment of Friedreich Ataxia, or FA, cardiomyopathy. Lex...
07-16 00:03
Lexeo Therapeutics Inc - Lx2006 Shows 11.4% Lvmi Reduction at 12 Months
07-15 18:02
Lexeo Therapeutics Inc - Lx2006 Was Well Tolerated With No Treatment-Related Se...
07-15 18:01